Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 18/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119124 | 0.95 | FDFT1 (0.73) | FDFT1 | |
| SCHEMBL4105280 | 0.94 | FDFT1 (0.71) | FDFT1 | |
| SCHEMBL4685905 | 0.88 | FDFT1 (0.82) | FDFT1 | |
| SCHEMBL7250136 | 0.88 | FDFT1 (0.90) | FDFT1 | |
| SCHEMBL7255888 | 0.88 | FDFT1 (1.00) | FDFT1 | |
| SCHEMBL7254399 | 0.87 | FDFT1 (0.90) | FDFT1 | |
| SCHEMBL7248923 | 0.87 | FDFT1 (1.00) | FDFT1 | |
| SCHEMBL4679220 | 0.87 | FDFT1 (0.61) | FDFT1 | |
| SCHEMBL7256146 | 0.86 | FDFT1 (0.89) | FDFT1 | |
| SCHEMBL7250335 | 0.86 | FDFT1 (0.99) | FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1097928-B1 | 5-(2,3-Dialkoxyphenyl)-4,1-benzoxazepin-2-ones as anti-hyperlipidemics | TAKEDA PHARMACEUTICAL (JP) | 2008-07-16 | — | — | EP | claimed |
| US-20040063750-A1 | High-density lipoprotein-cholesterol level elevating agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | claimed |
| EP-1332763-A1 | HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL LEVEL ELEVATING AGENT | Takeda Chemical Industries, Ltd. (JP) | 2003-08-06 | — | — | EP | claimed |
| EP-0862562-B1 | BENZOXAZEPINE COMPOUNDS, THEIR PRODUCTION AND USE AS LIPID LOWERING AGENTS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-07-04 | — | — | EP | claimed |
| US-6110909-A | SQUALENE SYNTHETASE INHIBITING ANTILIPEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-29 | — | — | US | claimed |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-20 | — | — | US | disclosed |
| US-20090118255-A1 | Crp Lowering Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-07 | — | — | US | disclosed |
| US-20090082333-A1 | REMEDY FOR XANTHOMA | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-15 | — | — | US | disclosed |
| US-20080058310-A1 | High-density lipoprotein-cholesterol level elevating agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1889632-A1 | REMEDY FOR XANTHOMA | National University Corp. Kobe University (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-20060052362-A1 | Skeletal muscle protecting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1600166-A1 | SKELETAL MUSCLE PROTECTING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2005-11-30 | — | — | EP | disclosed |
| US-20040063750-A1 | High-density lipoprotein-cholesterol level elevating agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1332763-A1 | HIGH-DENSITY LIPOPROTEIN-CHOLESTEROL LEVEL ELEVATING AGENT | Takeda Chemical Industries, Ltd. (JP) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082333-A1 | REMEDY FOR XANTHOMA | FDFT1, LSS, SQLE | FDFT1 1/4885 |
| US-20080058310-A1 | High-density lipoprotein-cholesterol level elevating agent | SREBF1, SREBF2, HDLBP | FDFT1 10/4885 |
| US-20090118255-A1 | Crp Lowering Agent | SPR, RBP1, HMGCR | FDFT1 7/4885 |
| US-20090209510-A1 | Novel Method of Treating Hyperlipidemia | HMGCR, LIPC, LIPA | FDFT1 12/4885 |
| US-20080113965-A1 | Compound having inhibitory activity against squalene synthase or a salt or prodrug thereof, for example, N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid; myalgia or rhabdomyolysis treatment | SQLE, DHPS, COASY | FDFT1 13/4885 |
| US-20060052362-A1 | Skeletal muscle protecting agent | GYS1, CPT1B, TNNC1 | FDFT1 8/4885 |
| US-20040063750-A1 | High-density lipoprotein-cholesterol level elevating agent | SREBF1, SREBF2, HDLBP | FDFT1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.